[Influence of somatastatin on oral glucose tolerance in autonomous hypersecretion of growth hormone, prolactin or insulin (author's transl)].
Oral glucose tolerance tests (OGTT) were performed for two subsequent days in 4 patients with active acromegaly, 2 patients with prolactin-producing pituitary adenomas and one insulinoma patient. Thirty minutes before the second OGTT 250 mug of somatostatin were injected intravenously as a bolus followed by a somatostatin infusion (500 mug) over 21/2 hours. The OGTTs were pathologic due to the hGH- and hPRL-induced insulin antagonism; they could not be normalized or improved by somatostatin. Only the peak of the blood sugar curve was shifted from one to two and a half hours after glucose administration; insulin and hGH levels were regularly suppressed after somatostatin whereas hPRL remained unchanged in most instances. Gastrin levels increased in all patients during the OGTT, the increase was suppressed in 4 patients. These findings show that the pathologic glucose tolerance due to insulin antagonism could not be improved by somatostatin in contrast to the deteriorated glucose tolerance in insulinopenic states.
D000172:Acromegaly / Q000097:blood*; D007516:Adenoma, Islet Cell / Q000097:blood*; D000284:Administration, Oral; D001786:Blood Glucose / Q000032:analysis; D005260:Female; D005755:Gastrins / Q000097:blood; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism; D005951:Glucose Tolerance Test; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D010911:Pituitary Neoplasms / Q000097:blood; D011388:Prolactin / Q000097:blood*; D013004:Somatostatin / Q000494:pharmacology*; D013997:Time Factors
D001786:Blood Glucose; D005755:Gastrins; D007328:Insulin; D013004:Somatostatin; D011388:Prolactin; D013006:Growth Hormone; D005947:Glucose
Einfluss von Somatostatin auf die orale Glucosetoleranz bei autonomer Mehrsekretion von Wachstumshormon, Prolaktin oder Insulin